1 / 25

Nausea and Vomiting

Nausea and Vomiting. Objectives. To get a detailed history and associated symptoms To get the DD To recognize and treat typhoid. Case Report.

psyche
Download Presentation

Nausea and Vomiting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Nausea and Vomiting

  2. Objectives • To get a detailed history and associated symptoms • To get the DD • To recognize and treat typhoid

  3. Case Report • A 29 year old woman G1/P0/Ab0 complains of severe, recurrent vomiting, worse in the morning but sometimes in the later part of the day, and failure to gain weight. She is in her 13th week of pregnancy. Her past medical history is negative except for obsessive-compulsive disorder. • What is her diagnosis?

  4. Terminology • Nausea: from the Latin naus ( a ship); a very unpleasant sensation that one may soon vomit • Retching: muscular activity of the abdomen and thorax, often voluntary, leading to forced inspiration against a closed mouth and glottis without oral discharge of gastric contents (“dry heaves”) • Vomiting: involuntary contractions of the abdominal, thoracic and GI (smooth) muscles leading to forceful expulsion of stomach contents from the mouth

  5. Terminology, cont’d • Regurgitation: effortless return of esophageal or gastric contents into the mouth unassociated with nausea or involuntary muscle contractions. • Rumination: food that is regurgitated in the postprandial period, re-chewed and then re-swallowed

  6. VOMITING PATHWAYS Ipecac syrup

  7. GI tract disorders toxins, infections, obstruction, inflammation, motility disorders Non-GI infections liver, CNS, renal, pneumonia, others Pregnancy Visceral inflammation pancreas, GB, peritoneum Myocardial ischemia or infarction Other CNS disorders migraine, neoplasm, bleed Vestibular disorders Metabolic/endocrine DKA, uremia, adrenal insufficiency, hyper- or hypothyroidism, hyper- or hypoparathyroidism Alcohol intoxication Psychogenic Radiation exposure Medications Common etiologies of nausea and vomiting

  8. Clues to psychogenic vomiting • Usually female and often young • May deny or minimize nausea • Rarely occurs in public or in front of others • Co-existent eating disorder, laxative abuse, diuretic abuse common • Psychological disturbances common • Complications of vomiting may be present

  9. Surreptitious vomiting: when to suspect it • Unexplained weight loss • Co-existent eating disorder or other psychological condition • Co-existent laxative and/or diuretic abuse • Electrolyte and/or acid-base disturbances consistent with vomiting, including hypo- kalemic nephropathy • Emetic complications (with denial of vomiting)

  10. Cancer chemotherapy e.g. cisplatin Analgesics e.g. opiates, NSAIDs Anti-arrythmics e.g., digoxin, quinidine Antibiotics e.g., erythromycin Oral contraceptives Metformin Anti-parkinsonians e.g., bromcryptine, L-DOPA Anti-convulsants e.g., phenytoin, carbamazepine Anti-hypertensives Theophylline Anesthetic agents Medications that often cause nausea and vomiting

  11. Complications of Vomiting • Nutritional • adults: weight loss; kids: failure to gain • Cutaneous (petechia, purpura) • Orophayngeal (dental, sore throat) • Esophagitis/ esophageal hematoma • GE Junctional: M-W tears; rupture (Boorhaave’s) • Metabolic: electrolyte, acid-base, water • Renal: prerenal azotemia; ATN; hypokalemic nephropathy

  12. Post-emetic purpura (“mask phenomenom) Cutis, 1986

  13. Nausea and Vomiting: Key Historical Questions • How long? • Relationship to meals? • Contents of vomitus? • Associated symptoms • pain in chest or abdomen, fever, myalgias, diarrhea, vertigo, dizziness, headache, focal neurological symptoms, jaundice, weight loss • Diabetes? • When was last menstrual period?

  14. Nausea and Vomiting: Key Physical Findings • Vital signs • BP and pulse tilt test • Cardiopulmonary exam • Abdominal exam • Rectal exam • Neurological exam including funduscopic exam (papilledema)

  15. Laboratory studies: guided by history and physical • Electrolytes, glucose, BUN/creatinine • Calcium, albumin, total serum proteins • Complete blood count (CBC) • Liver Function Tests • Pregnancy test • Urinalysis • Serum lipase  amylase

  16. Radiology studies: guided by history and physical • Plain abdominal films • Abdominal sono or CT if pain is key feature • Head CT or MRI if severe headache, papill-edema, marked hypertension, altered mental status, or focal neurological findings • EGD or upper GI to separate GOO or high duodenal obstruction from gastroparesis • Radiopaque marker emptying studies or radionuclide scintigraphy, esp. if diabetic

  17. Radio-opaque markers still in the stomach 6 hours after meal in a diabetic with nausea

  18. ALGORITHMIC APPROACH or marker

  19. Treatment of nausea and vomiting 1. Treat complications regardless of cause e.g., replace salt, water, potassium losses 2. Identify and treat underlying cause, whenever possible 3. Provide temporary symptomatic relief of the symptoms 4. Use preventive measures when vomiting is likely to occur (e.g., cancer chemotherapy, parenteral opiate administration)

  20. Drugs with anti- emetic prop-erties and known mechanisms • Antihistamines, e.g., meclizine (AntivertR) • esp. for vestibular disorders • Anticholinergics, e.g., scopolamine (Transderm ScopR, DonnatalR) • esp. for vestibular and GI disorders • Dopamine antagonists, e.g.,metoclopramide (ReglanR) or prochlorperazine (CompazineR) • esp. for GI disorders • Selective serotonin-3 (5HT3) RAs, e.g., odansetron, granisetron, dolasetron • esp. to prevent chemotherapy-induced nausea/vomiting

  21. Drugs with anti-emetic properties (continued) Multiple mechanisms of action: • Promethazine (PhenerganR) • dopamine antagonist • H1 antihistamine • anticholinergic • CNS sedative • prevention of opiate-induced nausea and vomiting • Hydroxyzine (AtaraxR, VistarilR) • H1 antihistamine • anticholinergic • CNS sedation • prevention of opiate-induced nausea and vomiting

  22. Drugs with anti-emetic properties (continued) Uncertain mechanism of action: • Trimethobenzamide (TiganR) • blocks apomorphine-induced emesis in dogs • does not block emesis from p.o. CuSO4 in dogs  probably acts in the chemoreceptor trigger zone (CTZ) of the medulla oblongata • Bismuth subsalicylate (Pepto-BismolR)

  23. Adjunctive antiemetic agents • Dexamethasone (DecadronR) • along with other anti-emetics for prevention of cancer chemotherapy-induced emesis • Dronabinol (MarinolR) • for prevention of cancer chemotherapy-induced emesis refractory to other agents • [ also for anorexia and weight loss in AIDS]

  24. Summary • Nausea and vomiting are features of many GI and non-GI diseases and disorders. • Regardless of its cause, treatment of nausea and vomiting should initially focus on replacing volume and electrolyte deficits. Later on, nutritional deficits must be addressed. • Regardless of its cause, nausea and vomiting can cause several life-threatening GI and non-GI complications. • Elucidation of the cause is often possible, and treatment of the underlying cause will usually be successful. • Effective symptomatic therapies for nausea and vomiting are available when the cause is unclear or when the treatment of the underlying cause takes time to work.

  25. Follow up on Case Report • The patient was diagnosed with hyperemesis gravidarum. • Her TSH was undetectable, her free T4 and serum T3 were markedly elevated. • Her symptoms resolved in a few weeks, without recurrence. Goodwin et al. Transient hyperthyroidism and hyperemesis gravidarum. Am J Obstet Gynecol 167: 648, 1992 and J. Clin Endocrin Metab 75: 1333, 1992

More Related